Michael Wall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Wall has a total of 606 co-authors. Here are the top co-authors by number of shared publications:
- Randy H. Kardon
Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, USA
23 shared publications - Chris A. Johnson
Univ. of California, Los Angeles (United States)
19 shared publications Michael P. McDermott
11 shared publicationsAndrew G. Lee
9 shared publicationsCarrie K. Doyle
Iowa City Veterans Affairs Health Care System, Iowa City, Iowa
8 shared publicationsJohn L. Keltner
Department of Ophthalmology and Vision Science, University of California Davis, Davis, California, United States 6Department of Neurology and Neurological Surgery, University of California Davis, Davis, California, United States
8 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3) , e000119
Systemic Metabolomic Changes in Idiopathic Intracranial Hypertension
Background and ObjectivesObesity is a well-established risk factor for idiopathic intracranial hypertension (IIH), yet the metabolic mechanisms linking obesity to IIH remain poorly understood. Prev...
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (3) , e000119
Open AccessSystemic Metabolomic Changes in Idiopathic Intracranial Hypertension
Background and ObjectivesObesity is a well-established risk factor for idiopathic intracranial hypertension (IIH), yet the metabolic mechanisms linking obesity to IIH remain poorly understood. Prev...
- 1 June 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 46 (2) , 271-278
What Have We Learned From the Idiopathic Intracranial Hypertension Treatment Trial the William F. Hoyt Lecture
Background: The Idiopathic Intracranial Hypertension Treatment Trial's (IIHTT) objective was to evaluate the efficacy and safety of acetazolamide, combined with a low-sodium weight-reduction diet, in improving visual function in patients with idiopathic intracranial hypertension (IIH) and mild visual loss. Methods: To accomplish this, a NEI-sponsored multicenter, double-blind, randomized, placebo-controlled clinical trial was performed at 38 North American clinical sites. A total of 165 participants (161 women; mean age 29 years) meeting the modified Dandy criteria with reproducible mild visual loss (perimetric mean deviation [PMD] −2 to −7 dB) were enrolled. Participants were randomized to acetazolamide or placebo, each combined with a structured dietary program. Acetazolamide was initiated at 1 g/day and titrated weekly to a maximum of 4 g/day. The primary outcome was change in PMD at 6 months. Treatment failure was defined by prespecified reproducible PMD worsening criteria. Secondary outcomes included papilledema grade, OCT metrics, cerebrospinal fluid (CSF) pressure, quality of life, weight change, and headache disability. Results: Acetazolamide produced greater PMD improvement than placebo (1.43 dB vs 0.71 dB; treatment effect 0.71 dB; P = 0.05) and the result was independent of weight loss. Participants with high-grade papilledema had the greatest benefit (2.27 dB). Acetazolamide significantly improved papilledema grade and OCT optic disc volume and reduced CSF pressure by an additional 60-mm H 2 O compared with placebo ( P = 0.002). Quality-of-life scores improved significantly with improvement in vision being the most important factor. Seven participants experienced treatment failure (6 placebo, 1 acetazolamide). Risk factors for treatment failure were high-grade papilledema, more than 30 transient visual obscurations per month, visual acuity loss, and male sex. Compliance of study drug was high (89% vs 93%). Tolerability was excellent when the maximal tolerated dosage was used with no permanent morbidity. Conclusions: Acetazolamide plus diet gave statistically significant improvements of visual function, papilledema, CSF pressure, and quality of life in patients with IIH with mild visual loss. A maximally tolerated dose up to 4 g/day is recommended.
- 1 June 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 46 (2) , 271-278
What Have We Learned From the Idiopathic Intracranial Hypertension Treatment Trial the William F. Hoyt Lecture
Background: The Idiopathic Intracranial Hypertension Treatment Trial's (IIHTT) objective was to evaluate the efficacy and safety of acetazolamide, combined with a low-sodium weight-reduction diet, in improving visual function in patients with idiopathic intracranial hypertension (IIH) and mild visual loss. Methods: To accomplish this, a NEI-sponsored multicenter, double-blind, randomized, placebo-controlled clinical trial was performed at 38 North American clinical sites. A total of 165 participants (161 women; mean age 29 years) meeting the modified Dandy criteria with reproducible mild visual loss (perimetric mean deviation [PMD] −2 to −7 dB) were enrolled. Participants were randomized to acetazolamide or placebo, each combined with a structured dietary program. Acetazolamide was initiated at 1 g/day and titrated weekly to a maximum of 4 g/day. The primary outcome was change in PMD at 6 months. Treatment failure was defined by prespecified reproducible PMD worsening criteria. Secondary outcomes included papilledema grade, OCT metrics, cerebrospinal fluid (CSF) pressure, quality of life, weight change, and headache disability. Results: Acetazolamide produced greater PMD improvement than placebo (1.43 dB vs 0.71 dB; treatment effect 0.71 dB; P = 0.05) and the result was independent of weight loss. Participants with high-grade papilledema had the greatest benefit (2.27 dB). Acetazolamide significantly improved papilledema grade and OCT optic disc volume and reduced CSF pressure by an additional 60-mm H 2 O compared with placebo ( P = 0.002). Quality-of-life scores improved significantly with improvement in vision being the most important factor. Seven participants experienced treatment failure (6 placebo, 1 acetazolamide). Risk factors for treatment failure were high-grade papilledema, more than 30 transient visual obscurations per month, visual acuity loss, and male sex. Compliance of study drug was high (89% vs 93%). Tolerability was excellent when the maximal tolerated dosage was used with no permanent morbidity. Conclusions: Acetazolamide plus diet gave statistically significant improvements of visual function, papilledema, CSF pressure, and quality of life in patients with IIH with mild visual loss. A maximally tolerated dose up to 4 g/day is recommended.
- 20 February 2026
- Published by Elsevier in Neurologic Clinics
- Vol. 44 (2) , 199-213
Update on Idiopathic Intracranial Hypertension
- 20 February 2026
- Published by Elsevier in Neurologic Clinics
- Vol. 44 (2) , 199-213
Update on Idiopathic Intracranial Hypertension
- 25 December 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (7) , 736-742
Archetypal analysis quantifies changes in patterns of visual field loss in eyes with acute non-arteritic anterior ischaemic optic neuropathy
Aims: We characterised visual field (VF) spatial loss patterns in acute non-arteritic anterior ischaemic optic neuropathy (NAION) using archetypal analysis (AA). Methods: We performed standard automated perimetry on 727 participants with acute NAION at screening, day 1 of enrolment, months 2, 6 and 12. We applied AA, an unsupervised machine learning technique, to identify and quantify distinct VF loss patterns (archetypes, ATs). We used Mann-Whitney U tests and Wilcoxon signed-rank tests to assess demographic differences and longitudinal changes in discrete variables, and linear regression to analyse continuous variables. Results: AA identified 10 distinct ATs, with three especially prevalent patterns: global VF loss (AT1), inferior altitudinal loss (AT2) and inferior altitudinal with macular sparing (AT3). Between day 1 and month 2, AT1 RW significantly increased from 15.7% to 28.1% (false discovery rate, FDR-adjusted p<0.001). Asian participants consistently exhibited greater RW for AT1 compared with White participants (day 1: 40.7% vs 17.7%; FDR-adjusted p<0.001). Sex differences emerged modestly at months 2 and 6, with females having a higher RW for superior altitudinal loss (FDR-adjusted p=0.049). Older participants showed slightly greater frequency of central horizontal and mild central depression patterns (FDR-adjusted p<0.001). Conclusions: AA effectively quantifies distinct, clinically significant VF spatial loss patterns in NAION, revealing significant temporal changes and demographic differences. Global VF loss represents the predominant AT, increasing notably within 2 months of disease onset. Prominent racial disparities, particularly higher severity in Asian individuals, underscore potential differences in NAION aetiology or susceptibility. These findings provide a foundation for improved disease characterisation and prognosis.
- 25 December 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (7) , 736-742
Archetypal analysis quantifies changes in patterns of visual field loss in eyes with acute non-arteritic anterior ischaemic optic neuropathy
Aims: We characterised visual field (VF) spatial loss patterns in acute non-arteritic anterior ischaemic optic neuropathy (NAION) using archetypal analysis (AA). Methods: We performed standard automated perimetry on 727 participants with acute NAION at screening, day 1 of enrolment, months 2, 6 and 12. We applied AA, an unsupervised machine learning technique, to identify and quantify distinct VF loss patterns (archetypes, ATs). We used Mann-Whitney U tests and Wilcoxon signed-rank tests to assess demographic differences and longitudinal changes in discrete variables, and linear regression to analyse continuous variables. Results: AA identified 10 distinct ATs, with three especially prevalent patterns: global VF loss (AT1), inferior altitudinal loss (AT2) and inferior altitudinal with macular sparing (AT3). Between day 1 and month 2, AT1 RW significantly increased from 15.7% to 28.1% (false discovery rate, FDR-adjusted p<0.001). Asian participants consistently exhibited greater RW for AT1 compared with White participants (day 1: 40.7% vs 17.7%; FDR-adjusted p<0.001). Sex differences emerged modestly at months 2 and 6, with females having a higher RW for superior altitudinal loss (FDR-adjusted p=0.049). Older participants showed slightly greater frequency of central horizontal and mild central depression patterns (FDR-adjusted p<0.001). Conclusions: AA effectively quantifies distinct, clinically significant VF spatial loss patterns in NAION, revealing significant temporal changes and demographic differences. Global VF loss represents the predominant AT, increasing notably within 2 months of disease onset. Prominent racial disparities, particularly higher severity in Asian individuals, underscore potential differences in NAION aetiology or susceptibility. These findings provide a foundation for improved disease characterisation and prognosis.
- Open Access
- 1 October 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 14 (10) , 12
Archetypal Analysis Reveals Consistent Visual Field Patterns for Stimulus Size III and Size Modulation Perimetry in Glaucoma
Optic nerve disorders produce identifiable visual field (VF) patterns. Size modulation perimetry (SMP) unlike standard automated perimetry (SAP) shows little degradation of retest variability with increasing VF damage. We hypothesize that VF testing with stimulus size III (size III) and SMP would reveal analogous patterns, supporting interchangeability in clinical practice. We analyzed 274 same-day pairs of VFs from 83 eyes of patients with glaucoma. Participants underwent testing every 6 months using size III and SMP VFs. We converted raw sensitivity data to total deviation (TD) scores relative to normative datasets, censoring size III sensitivities below 20 decibels (dB). Archetypal analysis (AA) was applied separately to each modality to identify characteristic VF patterns, or archetypes (ATs). We evaluated both absolute VF patterns and longitudinal VF changes by subtracting baseline measurements. Cosine similarity measured the overlap between ATs in size III and SMP. Absolute size III and SMP VFs exhibited overlapping patterns, with 95% of ATs demonstrating a cosine similarity of ≥0.50. Change ATs showed lower similarity scores (30% with cosine similarity ≥0.50). However, some ATs still revealed similar underlying defects. AA consistently extracted comparable VF defect patterns from size III and SMP in glaucoma. Absolute size III patterns closely aligned with SMP, whereas patterns of change showed partial agreement. These findings suggest that SAP and SMP capture similar patterns of VF loss.
- 1 October 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 14 (10) , 12
Open AccessArchetypal Analysis Reveals Consistent Visual Field Patterns for Stimulus Size III and Size Modulation Perimetry in Glaucoma
Optic nerve disorders produce identifiable visual field (VF) patterns. Size modulation perimetry (SMP) unlike standard automated perimetry (SAP) shows little degradation of retest variability with increasing VF damage. We hypothesize that VF testing with stimulus size III (size III) and SMP would reveal analogous patterns, supporting interchangeability in clinical practice. We analyzed 274 same-day pairs of VFs from 83 eyes of patients with glaucoma. Participants underwent testing every 6 months using size III and SMP VFs. We converted raw sensitivity data to total deviation (TD) scores relative to normative datasets, censoring size III sensitivities below 20 decibels (dB). Archetypal analysis (AA) was applied separately to each modality to identify characteristic VF patterns, or archetypes (ATs). We evaluated both absolute VF patterns and longitudinal VF changes by subtracting baseline measurements. Cosine similarity measured the overlap between ATs in size III and SMP. Absolute size III and SMP VFs exhibited overlapping patterns, with 95% of ATs demonstrating a cosine similarity of ≥0.50. Change ATs showed lower similarity scores (30% with cosine similarity ≥0.50). However, some ATs still revealed similar underlying defects. AA consistently extracted comparable VF defect patterns from size III and SMP in glaucoma. Absolute size III patterns closely aligned with SMP, whereas patterns of change showed partial agreement. These findings suggest that SAP and SMP capture similar patterns of VF loss.
- Open Access
Relating Standardized Automated Perimetry Performed with Stimulus Sizes III and V in Eyes With Field Loss due to Glaucoma and NAION
Objective Standard automated perimetry (SAP) visual field (VF) results are more repeatable using Goldmann stimulus size V (stimV) in eyes with moderate/severe deficits due to glaucoma. There are few reports relating VFs using stimulus size V and III, typically used in the clinic for glaucoma, and none for non-arteritic anterior ischemic optic neuropathy (NAION). We hypothesized that we could compare and relate the VFs with both stimuli for glaucoma and NAION. Methods We utilized 1992 same-day pairs of stimIII and stimV SAP VFs using the 24-2 strategy for eyes with glaucoma or NAION. We explored the optimal threshold to censor the raw sensitivities, prior to calculating age-standardized total deviations (TD). We determined the mean and standard deviation of the differences among all TD pairs. We computed a line of best fit to determine closeness to the line of unity. Results The ideal censoring conversion threshold was 21 dB for stimIII and 24 dB for stimV. The difference between stimV and stimIII censored (0.0 ± 1.9 dB) and uncensored (0.4 ± 2.6 dB) TD pairings strongly correlate with each other (r2 = 0.70, p < 0.001). The line of best fit from these pairings has a slope of 0.92, which is similar to that of the line of unity (m = 1). Conclusion Censoring plus age correction is a valid method of comparison between stimIII and stimV SAP VFs with moderate to severe VF loss due to optic nerve disorders. Translational Relevance StimIII and stimV TDs are interchangeable in clinical practice.
Open AccessRelating Standardized Automated Perimetry Performed with Stimulus Sizes III and V in Eyes With Field Loss due to Glaucoma and NAION
Objective Standard automated perimetry (SAP) visual field (VF) results are more repeatable using Goldmann stimulus size V (stimV) in eyes with moderate/severe deficits due to glaucoma. There are few reports relating VFs using stimulus size V and III, typically used in the clinic for glaucoma, and none for non-arteritic anterior ischemic optic neuropathy (NAION). We hypothesized that we could compare and relate the VFs with both stimuli for glaucoma and NAION. Methods We utilized 1992 same-day pairs of stimIII and stimV SAP VFs using the 24-2 strategy for eyes with glaucoma or NAION. We explored the optimal threshold to censor the raw sensitivities, prior to calculating age-standardized total deviations (TD). We determined the mean and standard deviation of the differences among all TD pairs. We computed a line of best fit to determine closeness to the line of unity. Results The ideal censoring conversion threshold was 21 dB for stimIII and 24 dB for stimV. The difference between stimV and stimIII censored (0.0 ± 1.9 dB) and uncensored (0.4 ± 2.6 dB) TD pairings strongly correlate with each other (r2 = 0.70, p < 0.001). The line of best fit from these pairings has a slope of 0.92, which is similar to that of the line of unity (m = 1). Conclusion Censoring plus age correction is a valid method of comparison between stimIII and stimV SAP VFs with moderate to severe VF loss due to optic nerve disorders. Translational Relevance StimIII and stimV TDs are interchangeable in clinical practice.
- Open Access
- 1 September 2023
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 12 (9) , 19
Validation of the Iowa Head-Mounted Open-Source Perimeter
Purpose: To assess the validity of visual field (VF) results from the Iowa Head-Mounted Display (HMD) Open-Source Perimeter and to test the hypothesis that VF defects and test–retest repeatability are similar between the HMD and Octopus 900 perimeters. Methods: We tested 20 healthy and nine glaucoma patients on the HMD and Octopus 900 perimeters using the Open Perimetry Interface platform with size V stimuli, a custom grid spanning the central 26° of the VF, and a ZEST thresholding algorithm. Historical data from the Humphrey Field Analyzer (HFA) were also analyzed. Repeatability was analyzed with the repeatability coefficient (RC), and VF defect detection was determined through side-by-side comparisons. Results: The pointwise RCs were 2.6 dB and 3.4 dB for the HMD and Octopus 900 perimeters in ocular healthy subjects, respectively. Likewise, the RCs were 4.2 dB and 3.5 dB, respectively, in glaucomatous patients. Limits of agreement between the HMD and Octopus 900 perimeters were ±4.6 dB (mean difference, 0.4 dB) for healthy patients and ±8.9 dB (mean difference, 0.1 dB) for glaucomatous patients. Retrospective analysis showed that pointwise RCs on the HFA2 perimeter were between 3.4 and 3.7 dB for healthy patients and between 3.9 and 4.7 dB for glaucoma patients. VF defects were similar between the HMD and Octopus 900 for glaucoma subjects. Conclusions: The Iowa Virtual Reality HMD Open-Source Perimeter is as repeatable as the Octopus 900 perimeter and is a more portable and less expensive alternative than traditional perimeters. Translational Relevance: This study demonstrates the validity of the visual field results from the Iowa HMD Open-Source Perimeter which may help expand perimetry access.
- 1 September 2023
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 12 (9) , 19
Open AccessValidation of the Iowa Head-Mounted Open-Source Perimeter
Purpose: To assess the validity of visual field (VF) results from the Iowa Head-Mounted Display (HMD) Open-Source Perimeter and to test the hypothesis that VF defects and test–retest repeatability are similar between the HMD and Octopus 900 perimeters. Methods: We tested 20 healthy and nine glaucoma patients on the HMD and Octopus 900 perimeters using the Open Perimetry Interface platform with size V stimuli, a custom grid spanning the central 26° of the VF, and a ZEST thresholding algorithm. Historical data from the Humphrey Field Analyzer (HFA) were also analyzed. Repeatability was analyzed with the repeatability coefficient (RC), and VF defect detection was determined through side-by-side comparisons. Results: The pointwise RCs were 2.6 dB and 3.4 dB for the HMD and Octopus 900 perimeters in ocular healthy subjects, respectively. Likewise, the RCs were 4.2 dB and 3.5 dB, respectively, in glaucomatous patients. Limits of agreement between the HMD and Octopus 900 perimeters were ±4.6 dB (mean difference, 0.4 dB) for healthy patients and ±8.9 dB (mean difference, 0.1 dB) for glaucomatous patients. Retrospective analysis showed that pointwise RCs on the HFA2 perimeter were between 3.4 and 3.7 dB for healthy patients and between 3.9 and 4.7 dB for glaucoma patients. VF defects were similar between the HMD and Octopus 900 for glaucoma subjects. Conclusions: The Iowa Virtual Reality HMD Open-Source Perimeter is as repeatable as the Octopus 900 perimeter and is a more portable and less expensive alternative than traditional perimeters. Translational Relevance: This study demonstrates the validity of the visual field results from the Iowa HMD Open-Source Perimeter which may help expand perimetry access.
- 30 March 2023
- Published by Elsevier in Ophthalmology
- Vol. 130 (8) , 854-862
Predicting Visual Field Worsening with Longitudinal OCT Data Using a Gated Transformer Network
- 30 March 2023
- Published by Elsevier in Ophthalmology
- Vol. 130 (8) , 854-862
Predicting Visual Field Worsening with Longitudinal OCT Data Using a Gated Transformer Network
- Open Access
- 6 April 2022
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Journal of Vision
- Vol. 22 (5) , 1
The Open Perimetry Initiative: A framework for cross-platform development for the new generation of portable perimeters
The Open Perimetry Initiative was formed in 2010 with the aim of reducing barriers to clinical research with visual fields and perimetry. Our two principal tools are the Open Perimetry Interface (OPI) and the visualFields package with analytical tools. Both are fully open source. The OPI package contains a growing number of drivers for commercially available perimeters, head-mounted devices, and virtual reality headsets. The visualFields package contains tools for the analysis and visualization of visual field data, including methods to compute deviation values and probability maps. We introduce a new frontend, the opiApp, that provides tools for customization for visual field testing and can be used as a frontend to run the OPI. The app can be used on the Octopus 900 (Haag-Streit), the Compass (iCare), the AP 7000 (Kowa), and the IMO (CREWT) perimeters, with permission from the device manufacturers. The app can also be used on Android phones with virtual reality headsets via a new driver interface, the PhoneHMD, implemented on the OPI. The use of the tools provided by the OPI library is showcased with a custom static automated perimetry test for the full visual field (up to 50 degrees nasally and 80 degrees temporally) developed with the OPI driver for the Octopus 900 and using visualFields for statistical analysis. With more than 60 citations in clinical and translational science journals, this initiative has contributed significantly to expand research in perimetry. The continued support of researchers, clinicians, and industry are key in transforming perimetry research into an open science.
- 6 April 2022
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Journal of Vision
- Vol. 22 (5) , 1
Open AccessThe Open Perimetry Initiative: A framework for cross-platform development for the new generation of portable perimeters
The Open Perimetry Initiative was formed in 2010 with the aim of reducing barriers to clinical research with visual fields and perimetry. Our two principal tools are the Open Perimetry Interface (OPI) and the visualFields package with analytical tools. Both are fully open source. The OPI package contains a growing number of drivers for commercially available perimeters, head-mounted devices, and virtual reality headsets. The visualFields package contains tools for the analysis and visualization of visual field data, including methods to compute deviation values and probability maps. We introduce a new frontend, the opiApp, that provides tools for customization for visual field testing and can be used as a frontend to run the OPI. The app can be used on the Octopus 900 (Haag-Streit), the Compass (iCare), the AP 7000 (Kowa), and the IMO (CREWT) perimeters, with permission from the device manufacturers. The app can also be used on Android phones with virtual reality headsets via a new driver interface, the PhoneHMD, implemented on the OPI. The use of the tools provided by the OPI library is showcased with a custom static automated perimetry test for the full visual field (up to 50 degrees nasally and 80 degrees temporally) developed with the OPI driver for the Octopus 900 and using visualFields for statistical analysis. With more than 60 citations in clinical and translational science journals, this initiative has contributed significantly to expand research in perimetry. The continued support of researchers, clinicians, and industry are key in transforming perimetry research into an open science.
- Open Access
- 31 October 2021
- Published by BMJ
- Vol. 5 (Suppl 1) , A9.1-A9
23 Extension of a university based perioperative medicine program to a distant rural hospital
Leadership at Fairview Range Medical Center initiated the project by approaching leadership of the University of Minnesota. Department of Anesthesiology at the University negotiated a contract to provide medical directorship of the operating room and medical directorship of perioperative medicine services. The current medical directors of both services at the University of Minnesota were appointed dual roles in each site. Medical Directors have monthly visits via scheduled air service to meet administrative, surgical and medical leadership. Development of a robust tele medicine program to provide preoperative, intraoperative and postoperative anesthesia care with video technology. Collaboration between rural hospitals and academic medical centers should facilitate provision of the best possible evidence based perioperative care for the largest surgical population. We have demonstrated the ability to use multiple platforms synergistically to collaborate on all facets of perioperative care. The cooperative venture has been well received by all providers and has energized care in both hospitals. Similar collaborations could greatly improve care and value for the 20% of the population that receives care at rural hospitals. While telemedicine has been described to assist preoperative assessment, this to the best of our knowledge is one of the only programs that offer real time intraoperative and postoperative anesthesia consultative management via tele medicine.
- 31 October 2021
- Published by BMJ
- Vol. 5 (Suppl 1) , A9.1-A9
Open Access23 Extension of a university based perioperative medicine program to a distant rural hospital
Leadership at Fairview Range Medical Center initiated the project by approaching leadership of the University of Minnesota. Department of Anesthesiology at the University negotiated a contract to provide medical directorship of the operating room and medical directorship of perioperative medicine services. The current medical directors of both services at the University of Minnesota were appointed dual roles in each site. Medical Directors have monthly visits via scheduled air service to meet administrative, surgical and medical leadership. Development of a robust tele medicine program to provide preoperative, intraoperative and postoperative anesthesia care with video technology. Collaboration between rural hospitals and academic medical centers should facilitate provision of the best possible evidence based perioperative care for the largest surgical population. We have demonstrated the ability to use multiple platforms synergistically to collaborate on all facets of perioperative care. The cooperative venture has been well received by all providers and has energized care in both hospitals. Similar collaborations could greatly improve care and value for the 20% of the population that receives care at rural hospitals. While telemedicine has been described to assist preoperative assessment, this to the best of our knowledge is one of the only programs that offer real time intraoperative and postoperative anesthesia consultative management via tele medicine.